Weight-loss drugs spur debate and open new doors for CU Anschutz researcher studying food/brain relationshipOccasionally ...

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis ...